ArticleScientific reports2026
Attribute development for a discrete choice experiment to examine preferences for long-acting HIV prevention products among pregnant and breastfeeding women.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The application of discrete choice experiments (DCEs) is gaining popularity as a means of exploring preferences on health-related issues. The quality and validity of DCEs largely depend on the formative phase of attribute development. This paper documents a systematic attribute development process for a DCE assessing preferences for long-acting HIV prevention products among pregnant and breastfeeding women (PBFW) in Kenya. We applied the Helter and Boehler four-stage attribute development framework, comprising raw data collection, data reduction, removal of inappropriate attributes, and appropriate wording. Through literature review and qualitative approaches, we identified twelve attributes for products formulated as oral tablets, injections, vaginal rings, and implants. Six of the twelve attributes were considered plausible, salient, and capable of being traded, namely dosing frequency, effectiveness in HIV prevention, ability to prevent pregnancy, ability to prevent sexually transmitted infections, product access location, and product cost. A pilot among thirty PBFW confirmed the clarity and relevance of the six attributes, informing their inclusion in the DCE. Documenting this transparent step-by-step process improves transparency and facilitates objective evaluation of the DCE's formative phase. These findings contribute to methodological rigour in DCE design and provide empirical evidence for expanding preference-based HIV prevention strategies that will benefit PBFW.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.